Sutro Biopharma, Inc. (STRO) financial statements (2021 and earlier)

Company profile

Business Address 310 UTAH AVE., SUITE 150
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments118204
Cash and cash equivalents5125
Short-term investments11379
Receivables73
Other undisclosed current assets32
Total current assets:129210
Noncurrent Assets
Property, plant and equipment1011
Long-term investments and receivables16 
Long-term investments16 
Restricted cash and investments00
Other noncurrent assets32
Total noncurrent assets:2813
TOTAL ASSETS:156223
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities129
Accounts payable63
Accrued liabilities66
Deferred revenue19
Debt15
Contract with customer, liability22
Other liabilities11
Total current liabilities:3336
Noncurrent Liabilities
Long-term debt and lease obligation910
Long-term debt, excluding current maturities910
Liabilities, other than long-term debt1745
Deferred revenue16
Contract with customer, liability45
Deferred rent credit00
Other liabilities00
Total noncurrent liabilities:2655
Total liabilities:5992
Stockholders' equity
Stockholders' equity attributable to parent98132
Common stock00
Additional paid in capital293282
Accumulated other comprehensive income (loss)0(0)
Accumulated deficit(196)(150)
Total stockholders' equity:98132
TOTAL LIABILITIES AND EQUITY:156223

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Revenue from related parties23 
Gross profit:4338
Operating expenses(98)(76)
Operating loss:(55)(37)
Nonoperating income44
Investment income, nonoperating42
Other nonoperating income 2
Interest and debt expense(1)(2)
Loss before gain (loss) on sale of properties:(52)(35)
Other undisclosed net loss(3) 
Net loss available to common stockholders, diluted:(56)(35)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(56)(35)
Comprehensive loss:(56)(35)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)
Comprehensive loss, net of tax, attributable to parent:(56)(35)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: